Reistone Biopharma Company
Latest round
- Series A
Last raised
- May 2022
Total raised
- $100M
Investors
- 5
About Reistone Biopharma Company
Founded in 2018 and based in Shanghai, China, Reistone Biopharma Company Limited is a clinical-stage biopharmaceutical company focused on developing novel medicines for patients suffering from immuno-inflammatory disorders. Min Wang Irwin is the CEO and co-founder of the company. The company provides its core program SHR0302, a JAK1 inhibitor that is in phase III clinical trial after meeting endpoints in phase II studies in atopic dermatitis, ulcerative colitis, and alopecia areata. The firm's other products include SHR1459, an orally bioavailable, potent BTK inhibitor, as well as RS1805, a gut-selective RORgt inhibitor.
Who invested in Reistone Biopharma Company
5 investors across 1 round
See all investors in Reistone Biopharma Company
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 9, 2022
Amount
$100M
Investors
Questions about Reistone Biopharma Company
Who invested in Reistone Biopharma Company?
Reistone Biopharma Company has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Reistone Biopharma Company raised?
Reistone Biopharma Company has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Reistone Biopharma Company last raise money?
Reistone Biopharma Company's most recent round on record is a Series A, in May 2022.
What does Reistone Biopharma Company do?
Founded in 2018 and based in Shanghai, China, Reistone Biopharma Company Limited is a clinical-stage biopharmaceutical company focused on developing novel medicines for patients suffering from immuno-inflammatory disorders.
Where is Reistone Biopharma Company headquartered?
Reistone Biopharma Company is headquartered in Shanghai, China.
Which VCs invest in companies like Reistone Biopharma Company?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Reistone Biopharma Company's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Reistone Biopharma Company? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.